Randomized, placebo-controlled, multicenter, global Phase 3 trial will investigate the safety and efficacy of VIR-7831 in hospitalized adults with COVID-19
SAN FRANCISCO and LONDON, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the first patient has been dosed in a new sub-trial of the National Institutes of Healths (NIH) Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Program Phase 3 clinical trial. This trial is designed to evaluate the safety and efficacy of VIR-7831 for the treatment of hospitalized adults with COVID-19. VIR-7831 (also known as GSK4182136) is a fully human anti-SARS-CoV-2 (Severe Acute Respiratory Syndrome coronavirus-2) investigational monoclonal antibody that was selected based on its potential to neutralize the virus, kill infected cells, provide a high barrier to resistance and achieve high concentrations in the lungs (one of the major sites of infection).
ACTIV-3 is one of several ongoing trials in the NIHs ACTIV program, an NIH led public-private partnership designed to accelerate development of the most promising treatments and vaccine candidates for COVID-19. ACTIV-3 has been designed as a master protocol that allows for the simultaneous evaluation of multiple investigational therapeutics as they become available, but within the same clinical trial structure, across multiple trial sites.
George Scangos, Ph.D., chief executive officer of Vir, said: Recent data suggest that the neutralizing activity of antibodies may be insufficient to protect hospitalized adults from the most severe consequences of COVID-19. We are hopeful that the differentiating factors and broad anti-coronavirus activity of VIR-7831 may allow it to help those patients and add to our preparedness for related coronaviruses that could emerge in the future.
Dr. Hal Barron, chief scientific officer and president R&D, GSK, said: With new infection and hospitalization rates reaching record highs, the world needs multiple options to help combat this pandemic. We are developing solutions to fight this virus, from prevention through treatment, to provide relief from COVID-related illness. Our treatment option, VIR-7831, which has a high barrier to resistance and has the potential to neutralize the virus and kill infected cells, could allow this treatment to be effective for patients in hospital settings, where other antibodies have so far not shown an impact.
Story continues
In addition to the Phase 3 ACTIV-3 trial, VIR-7831 is also being evaluated in the global Phase 2/3 COMET-ICE (COVID-19 Monoclonal antibody Efficacy Trial - Intent to Care Early) trial for the early treatment of COVID-19 in adults at high risk of hospitalization. The Phase 3 part of the COMET-ICE trial is assessing the safety and efficacy of a single intravenous (IV) infusion of VIR-7831 or placebo in approximately 1,300 non-hospitalized participants globally. The primary efficacy endpoint is the proportion of adults who have progression of COVID-19 as defined by the need for hospitalization or death within 29 days of randomization. The COMET clinical development program for VIR-7831 also includes a planned Phase 3 trial for the prevention of symptomatic infection.
ACTIV-3 Clinical Trial DesignThe ACTIV-3 trial arm evaluating VIR-7831 will initially compare 300 participants who have been hospitalized with mild to moderate COVID-19 with fewer than 13 days of symptoms, who will receive either VIR-7831 or placebo. Participants also will receive standard care for COVID-19, including the FDA-approved antiviral remdesivir. Five days after dosing, participants clinical status will be assessed, based on need for supplemental oxygen, mechanical ventilation, or other supportive care. If the VIR-7831 treatment arm appears to have a positive benefit:risk profile, the trial will enroll an additional 700 participants, including those who are more severely ill (i.e., adults with organ failure requiring mechanical support, or COVID-19-associated dysfunction of organs other than the lungs). Trial participants will be followed for 90 days following enrollment to analyze their response to treatment. The primary efficacy endpoint is the participants sustained recovery for 14 days after release from the hospital.
About VIR-7831 / GSK4182136VIR-7831 (GSK4182136) is a monoclonal antibody for which preclinical data suggest its ability to neutralize SARS-CoV-2 live virus in vitro and in vivo. The antibody binds to an epitope on SARS-CoV-2 that is shared with SARS-CoV-1 (also known as SARS), indicating that the epitope is highly conserved, which may make it more difficult for resistance to develop. VIR-7831/GSK4182136 has been engineered with the potential to enhance lung bioavailability and have an extended half-life.
About the Vir and GSK CollaborationIn April 2020, Vir and GSK entered into a collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2, the virus that causes COVID-19. The collaboration uses Virs proprietary monoclonal antibody platform technology to accelerate existing and identify new anti-viral antibodies that could be used as therapeutic or preventive options to help address the current COVID-19 pandemic and future outbreaks. The companies will leverage GSKs expertise in functional genomics and combine their capabilities in CRISPR screening and artificial intelligence to identify anti-coronavirus compounds that target cellular host genes. They will also apply their combined expertise to research SARS-CoV-2 and other coronavirus vaccines.
About Vir BiotechnologyVir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting SARS-CoV-2, hepatitis B virus, influenza A, human immunodeficiency virus and tuberculosis. For more information, please visit http://www.vir.bio.
About GSK GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit http://www.gsk.com/about-us.
Vir Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as may, will, plan, potential, aim, promising and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Virs expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include statements regarding the potential benefits of VIR-7831 in treating hospitalized patients with COVID-19, the potential benefits of participating in the ACTIV-3 trial, the ability of using a combination of a potent effector function and neutralization capabilities in enhancing the efficacy of monoclonal antibodies to treat hospitalized patients, the efficacy and safety of a single intravenous (IV) infusion of VIR-7831, Virs plans around the evaluation of interim analyses and the expected timing of clinical study results for VIR-7831, the ability of VIR-7831 to prevent symptomatic infection, the clinical trial design around ACTIV-3 as well as statements around the potential benefits of Vir and GSKs collaboration in addressing the current COVID-19 pandemic and future outbreaks of the disease. Many factors may cause differences between current expectations and actual results, including delays or failures in planned patient enrollment or retention, clinical site activation rates or clinical trial enrollment rates that are lower than expected, unexpected safety or efficacy data observed during preclinical or clinical studies, challenges in the treatment of hospitalized patients, difficulties in collaborating with other companies or government agencies, challenges in accessing manufacturing capacity, successful development and/or commercialization of alternative product candidates by our competitors, changes in expected or existing competition, delays in or disruptions to our business or clinical trials due to the COVID-19 pandemic, geopolitical changes or other external factors, and unexpected litigation or other disputes.
GSK Cautionary Statement Regarding Forward-Looking StatementsGSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D "Risk Factors" in the company's Annual Report on Form 20-F for 2019 and as set out in GSKs Principal risks and uncertainties section of the Q2 Results and any impacts of the COVID-19 pandemic.
Registered in England & Wales:No. 3888792
Registered Office:980 Great West RoadBrentford, MiddlesexTW8 9GS
View original post here:
Vir Biotechnology and GSK Announce Start of NIH-Sponsored ACTIV-3 Trial Evaluating VIR-7831 in Hospitalized Adults with COVID-19 - Yahoo Finance
- Production of ethanol from winter barley by the EDGE (enhanced dry grind enzymatic) process [Last Updated On: August 17th, 2024] [Originally Added On: April 29th, 2010]
- A high-throughput transient gene expression system for switchgrass (Panicum virgatum L.) seedlings [Last Updated On: August 17th, 2024] [Originally Added On: May 8th, 2010]
- Cellulose crystallinity index: measurement techniques and their impact on interpreting cellulase performance [Last Updated On: August 17th, 2024] [Originally Added On: May 25th, 2010]
- Comparing the fermentation performance of Escherichia coli KO11, Saccharomyces cerevisiae 424A(LNH-ST) and Zymomonas mobilis AX101 for cellulosic ethanol production [Last Updated On: August 17th, 2024] [Originally Added On: May 28th, 2010]
- Enzymatic digestibility and ethanol fermentability of AFEX-treated starch-rich lignocellulosics such as corn silage and whole corn plant [Last Updated On: August 17th, 2024] [Originally Added On: June 10th, 2010]
- Improved xylose and arabinose utilization by an industrial recombinant Saccharomyces cerevisiae strain using evolutionary engineering [Last Updated On: August 17th, 2024] [Originally Added On: June 16th, 2010]
- Effects of enzyme feeding strategy on ethanol yield in fed-batch simultaneous saccharification and fermentation of spruce at high dry matter [Last Updated On: August 17th, 2024] [Originally Added On: June 26th, 2010]
- Impact of dual temperature profile in dilute acid hydrolysis of spruce for ethanol production [Last Updated On: August 17th, 2024] [Originally Added On: July 2nd, 2010]
- Ethanol production from mixtures of wheat straw and wheat meal [Last Updated On: August 17th, 2024] [Originally Added On: July 6th, 2010]
- Earning Cash – Selling Old Mobile Phones [Last Updated On: August 17th, 2024] [Originally Added On: July 7th, 2010]
- Earning Cash – Selling Old Mobile Phones [Last Updated On: August 17th, 2024] [Originally Added On: July 7th, 2010]
- Improving simultaneous saccharification and co-fermentation of pretreated wheat straw using both enzyme and substrate feeding [Last Updated On: August 17th, 2024] [Originally Added On: August 3rd, 2010]
- Practical screening of purified cellobiohydrolases and endoglucanases with alpha-cellulose and specification of hydrodynamics [Last Updated On: August 17th, 2024] [Originally Added On: October 11th, 2010]
- Techno-economic evaluation of stillage treatment with anaerobic digestion in a softwood-to-ethanol process [Last Updated On: August 17th, 2024] [Originally Added On: October 11th, 2010]
- Cross-reactions between engineered xylose and galactose pathways in recombinant Saccharomyces cerevisiae [Last Updated On: August 17th, 2024] [Originally Added On: October 11th, 2010]
- Rapid optimization of enzyme mixtures for deconstruction of diverse pretreatment/biomass feedstock combinations [Last Updated On: August 17th, 2024] [Originally Added On: October 13th, 2010]
- Automated saccharification assay for determination of digestibility in plant materials [Last Updated On: August 17th, 2024] [Originally Added On: November 7th, 2010]
- Biodetoxification of toxins generated from lignocellulose pretreatment using a newly isolated fungus, Amorphotheca resinae ZN1, and the consequent ethanol fermentation [Last Updated On: August 17th, 2024] [Originally Added On: November 28th, 2010]
- Lignin monomer composition affects Arabidopsis cell-wall degradability after liquid hot water pretreatment [Last Updated On: August 17th, 2024] [Originally Added On: December 11th, 2010]
- Thermostable endoglucanases in the liquefaction of hydrothermally pretreated wheat straw [Last Updated On: August 17th, 2024] [Originally Added On: February 6th, 2011]
- Cellulose accessibility limits the effectiveness of minimum cellulase loading on the efficient hydrolysis of pretreated lignocellulosic substrates [Last Updated On: August 17th, 2024] [Originally Added On: February 14th, 2011]
- Arsenal of plant cell wall degrading enzymes reflects host preference among plant pathogenic fungi [Last Updated On: August 17th, 2024] [Originally Added On: February 16th, 2011]
- Hemicellulases and auxiliary enzymes for improved conversion of lignocellulosic biomass to monosaccharides [Last Updated On: August 17th, 2024] [Originally Added On: February 22nd, 2011]
- Two-step synthesis of fatty acid ethyl ester from soybean oil catalyzed by Yarrowia lipolytica lipase [Last Updated On: August 17th, 2024] [Originally Added On: March 6th, 2011]
- Topochemical distribution of lignin and hydroxycinnamic acids in sugar-cane cell walls and its correlation with the enzymatic hydrolysis of polysaccharides [Last Updated On: August 17th, 2024] [Originally Added On: March 17th, 2011]
- Direct ethanol production from cellulosic materials using a diploid strain of Saccharomyces cerevisiae with optimized cellulase expression [Last Updated On: August 17th, 2024] [Originally Added On: April 17th, 2011]
- Isolation of xylose isomerases by sequence- and function-based screening from a soil metagenome library [Last Updated On: August 17th, 2024] [Originally Added On: May 8th, 2011]
- Low temperature lignocellulose pretreatment: effects and interactions of pretreatment pH are critical for maximizing enzymatic monosaccharide yields from wheat straw [Last Updated On: August 17th, 2024] [Originally Added On: May 15th, 2011]
- Effect of mixing on enzymatic hydrolysis of steam-pretreated spruce: a quantitative analysis of conversion and power consumption [Last Updated On: August 17th, 2024] [Originally Added On: May 15th, 2011]
- Thermostable recombinant xylanases from Nonomuraea flexuosa and Thermoascus aurantiacus show distinct properties in the hydrolysis of xylans and pretreated wheat straw [Last Updated On: August 17th, 2024] [Originally Added On: May 22nd, 2011]
- Investigation of tension wood formation and 2,6-dichlorbenzonitrile application in short rotation coppice willow composition and enzymatic saccharification [Last Updated On: August 17th, 2024] [Originally Added On: May 29th, 2011]
- Aiming the complete utilization of sugar beet pulp through mild acid and hydrothermal pretreatment followed by enzymatic digestion [Last Updated On: August 17th, 2024] [Originally Added On: June 5th, 2011]
- Alkaline peroxide pretreatment of corn stover: effects of biomass, peroxide, and enzyme loading and composition on yields of glucose and xylose [Last Updated On: August 17th, 2024] [Originally Added On: June 12th, 2011]
- In-situ lignocellulosic unlocking mechanism in termite for carbohydrate hydrolysis: critical lignin modification [Last Updated On: August 17th, 2024] [Originally Added On: June 19th, 2011]
- Supplementation with xylanase and beta-xylosidase to reduce xylo-oligomer and xylan inhibition of enzymatic hydrolysis of cellulose and pretreated corn stover [Last Updated On: August 17th, 2024] [Originally Added On: June 26th, 2011]
- Co-hydrolysis of hydrothermal and dilute acid pretreated Populus slurries to support development of a high-throughput pretreatment system [Last Updated On: August 17th, 2024] [Originally Added On: July 17th, 2011]
- Evaluation of preservation methods for improving biogas production and enzymatic conversion yields of annual crops [Last Updated On: August 17th, 2024] [Originally Added On: July 24th, 2011]
- Simultaneous saccharification and co-fermentation of lignocellulosic residues from commercial furfural production and corn kernels using different nutrient media [Last Updated On: August 17th, 2024] [Originally Added On: July 31st, 2011]
- Increased isobutanol production in Saccharomyces cerevisiae by overexpression of genes in valine metabolism [Last Updated On: August 17th, 2024] [Originally Added On: July 31st, 2011]
- Bioprospecting metagenomics of decaying wood: mining for new glycoside hydrolases [Last Updated On: August 17th, 2024] [Originally Added On: August 7th, 2011]
- Functional characterization of cellulases identified from the cow rumen fungus neocallimastix patriciarum W5 by transcriptomic and secretomic analyses [Last Updated On: August 17th, 2024] [Originally Added On: August 21st, 2011]
- Simultaneous utilization of glucose and xylose for lipid production by Trichosporon cutaneum [Last Updated On: August 17th, 2024] [Originally Added On: August 28th, 2011]
- Conversion of deoxynivalenol to 3-acetyldeoxynivalenol in barley derived fuel ethanol co-products with yeast expressing trichothecene 3-O-acetyltransferases [Last Updated On: August 17th, 2024] [Originally Added On: September 4th, 2011]
- Comparative performance of precommercial cellulases hydrolyzing pretreated corn stover [Last Updated On: August 17th, 2024] [Originally Added On: September 11th, 2011]
- Impact of pretreatment and downstream processing technologies on economics and energy use in cellulosic ethanol production [Last Updated On: August 17th, 2024] [Originally Added On: September 11th, 2011]
- A kinetic model for quantitative evaluation of the effect of H2 and osmolarity on hydrogen production by Caldicellulosiruptor saccharolyticus [Last Updated On: August 17th, 2024] [Originally Added On: September 18th, 2011]
- High level secretion of cellobiohydrolases by Saccharomyces cerevisiae [Last Updated On: August 17th, 2024] [Originally Added On: September 18th, 2011]
- How recombinant swollenin from Kluyveromyces lactis affects cellulosic substrates and accelerates their hydrolysis [Last Updated On: August 17th, 2024] [Originally Added On: September 25th, 2011]
- Bio-conversion of paper sludge to biofuel by simultaneous saccharification and fermentation using a cellulase of paper sludge origin and thermotolerant Saccharomyces cerevisiae TJ14 [Last Updated On: August 17th, 2024] [Originally Added On: October 2nd, 2011]
- Biogenic hydrogen and methane production from Chlorella vulgaris and Dunaliella tertiolecta biomass [Last Updated On: August 17th, 2024] [Originally Added On: October 2nd, 2011]
- The enhancement of enzymatic hydrolysis of lignocellulosic substrates by the addition of accessory enzymes such as xylanase: is it an additive or synergistic effect? [Last Updated On: August 17th, 2024] [Originally Added On: October 9th, 2011]
- Biotechnology [Last Updated On: August 17th, 2024] [Originally Added On: October 10th, 2011]
- Biology: Biotechnology: Gene Cloning [Last Updated On: August 17th, 2024] [Originally Added On: October 10th, 2011]
- What Does a Biotechnology Course Look Like? [Last Updated On: August 17th, 2024] [Originally Added On: October 10th, 2011]
- Demo day by SCT Biotechnology Branch 2011 passouts [Last Updated On: August 17th, 2024] [Originally Added On: October 12th, 2011]
- Biotechnology Program Video [Last Updated On: August 17th, 2024] [Originally Added On: October 12th, 2011]
- Introduction To Industrial Biotechnology [Last Updated On: August 17th, 2024] [Originally Added On: October 13th, 2011]
- MSc Molecular Biotechnology -- Come to the School of Biosciences, University of Birmingham, UK - Video [Last Updated On: August 17th, 2024] [Originally Added On: October 13th, 2011]
- Oxbridge Biotechnology Roundtable - Video [Last Updated On: August 17th, 2024] [Originally Added On: October 15th, 2011]
- fermentation technology (biotechnology practical class) UNIVERSITY OF MALAYA - Video [Last Updated On: August 17th, 2024] [Originally Added On: October 15th, 2011]
- Biotechnology: Learn about New Biological Medicines in Development - Video [Last Updated On: August 17th, 2024] [Originally Added On: October 15th, 2011]
- Improving L-arabinose utilization of pentose fermenting Saccharomyces cerevisiae cells by heterologous expression of L-arabinose transporting sugar transporters [Last Updated On: August 17th, 2024] [Originally Added On: October 16th, 2011]
- The promoting effect of by-products from Irpex lacteus on subsequent enzymatic hydrolysis of bio-pretreated cornstalks [Last Updated On: August 17th, 2024] [Originally Added On: October 16th, 2011]
- Biotechnology - Video [Last Updated On: August 17th, 2024] [Originally Added On: October 16th, 2011]
- BiotechNaukri #Biotechnology Jobs - Video [Last Updated On: August 17th, 2024] [Originally Added On: October 16th, 2011]
- bio-technology - Video [Last Updated On: August 17th, 2024] [Originally Added On: October 16th, 2011]
- BioBytes - Biotechnology and food flavoring - Video [Last Updated On: August 17th, 2024] [Originally Added On: October 19th, 2011]
- Stine Biotechnology - Video [Last Updated On: August 17th, 2024] [Originally Added On: October 22nd, 2011]
- Effects of alkaline or liquid-ammonia treatment on crystalline cellulose: Changes in crystalline structure and effects on enzymatic digestibility [Last Updated On: August 17th, 2024] [Originally Added On: October 23rd, 2011]
- Transcriptome analysis of Aspergillus niger grown on sugarcane bagasse [Last Updated On: August 17th, 2024] [Originally Added On: October 23rd, 2011]
- A cellular automaton model of crystalline cellulose hydrolysis by cellulases [Last Updated On: August 17th, 2024] [Originally Added On: October 23rd, 2011]
- Application of a Burkholderia cepacia lipase-immobilized silica monolith to the batch and continuous biodiesel production with a stoichiometric mixture of methanol and crude Jatropha oil [Last Updated On: August 17th, 2024] [Originally Added On: October 23rd, 2011]
- Algal Biotechnology - Video [Last Updated On: August 17th, 2024] [Originally Added On: October 24th, 2011]
- Techniques of Biotechnology, Part 1 of 4 - Video [Last Updated On: August 17th, 2024] [Originally Added On: October 25th, 2011]
- Biotechnology days in Macedonia II - Video [Last Updated On: August 17th, 2024] [Originally Added On: October 26th, 2011]
- BioBytes: Forensics and Biotechnology - Video [Last Updated On: August 17th, 2024] [Originally Added On: October 26th, 2011]
- Faces of Biotechnology: What is Biotechnology - Video [Last Updated On: August 17th, 2024] [Originally Added On: October 26th, 2011]
- Mucosal and systemic responses/Dr Thomas Muster-AVIR Green Hills Biotechnology-World Vaccine - Video [Last Updated On: August 17th, 2024] [Originally Added On: October 26th, 2011]
- Unlimited Income Potential in Bio-Technology, Part 1 - Video [Last Updated On: August 17th, 2024] [Originally Added On: October 27th, 2011]
- Islam Ahmadiyya Questions: Biotechnology, Portraits, Ring, Prayers, Dreams, Adopted Children - Video [Last Updated On: August 17th, 2024] [Originally Added On: October 28th, 2011]